News
ZLSCF
0.480
NaN%
--
ZYUS Life Sciences cancels brokered offering, plans C$7M private placement, expands credit facility
Seeking Alpha · 02/25 12:52
Weekly Report: what happened at ZLSCF last week (0908-0912)?
Weekly Report · 09/15/2025 12:14
Weekly Report: what happened at ZLSCF last week (0901-0905)?
Weekly Report · 09/08/2025 12:17
Weekly Report: what happened at ZLSCF last week (0825-0829)?
Weekly Report · 09/01/2025 12:10
Weekly Report: what happened at ZLSCF last week (0818-0822)?
Weekly Report · 08/25/2025 12:26
Weekly Report: what happened at ZLSCF last week (0811-0815)?
Weekly Report · 08/18/2025 12:14
Weekly Report: what happened at ZLSCF last week (0804-0808)?
Weekly Report · 08/11/2025 12:25
Weekly Report: what happened at ZLSCF last week (0728-0801)?
Weekly Report · 08/04/2025 12:29
Weekly Report: what happened at ZLSCF last week (0721-0725)?
Weekly Report · 07/28/2025 12:29
Weekly Report: what happened at ZLSCF last week (0714-0718)?
Weekly Report · 07/21/2025 12:15
Weekly Report: what happened at ZLSCF last week (0707-0711)?
Weekly Report · 07/14/2025 12:29
Weekly Report: what happened at ZLSCF last week (0630-0704)?
Weekly Report · 07/07/2025 12:16
Weekly Report: what happened at ZLSCF last week (0623-0627)?
Weekly Report · 06/30/2025 12:25
Weekly Report: what happened at ZLSCF last week (0616-0620)?
Weekly Report · 06/23/2025 12:14
Weekly Report: what happened at ZLSCF last week (0609-0613)?
Weekly Report · 06/16/2025 12:24
More
Webull provides a variety of real-time ZLSCF stock news. You can receive the latest news about Zyus Life Sciences Corporation through multiple platforms. This information may help you make smarter investment decisions.
About ZLSCF
ZYUS Life Sciences Corporation is a Canada-based life sciences company focused on developing and commercializing cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.